The Course of Adverse Events in Venlafaxine XR Treatment in Generalized Anxiety Disorder

被引:3
|
作者
Rickels, Karl [1 ]
Gallop, Robert [2 ]
Cleary, Sean [3 ]
机构
[1] Univ Penn, Dept Psychiat, 3535 Market St,Suite 670, Philadelphia, PA 19146 USA
[2] West Chester Univ, Dept Math, Appl Stat Program, W Chester, PA USA
[3] Harcum Coll, Dept Gen Studies, Media, PA USA
关键词
adverse events; generalized anxiety disorder; attrition; TOLERABILITY;
D O I
10.1097/JCP.0000000000001027
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose The time course of adverse events is an important factor for patient management. Clinicians are better able to prepare patients for specific adverse events, which leads to better treatment adherence. Methods Adverse events were followed longitudinally for 6 months during the open-label phase of a relapse prevention trial with 264 patients with generalized anxiety disorder. Adverse events were assessed at each treatment visit using a 21-item checklist. Logistic regression modeling, continuation ratio modeling, and hierarchical linear modeling were used to determine whether adverse events led to early attrition and whether adverse events decreased in enrolled patients over time. Findings Adverse events were found to have decreased highly significantly during treatment. A highly significant race effect was found in that whites had a significantly higher adverse event rate than did nonwhites. Early attrition rates were predicted by presence of nausea and fatigue, late attrition by dizziness, nervousness, and sexual dysfunction.
引用
下载
收藏
页码:258 / 260
页数:3
相关论文
共 50 条
  • [31] Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder
    Lohoff, F. W.
    Aquino, T. D.
    Narasimhan, S.
    Multani, P. K.
    Etemad, B.
    Rickels, K.
    PHARMACOGENOMICS JOURNAL, 2013, 13 (01): : 21 - 26
  • [32] Serotonin Receptor 2A (HTR2A) Gene Polymorphism Predicts Treatment Response to Venlafaxine XR in Generalized Anxiety Disorder
    Lohoff, Falk W.
    Richardson, Tiffany
    Bloch, Paul
    Hodge, Rachel
    Doyle, Glenn
    Etemad, Bijan
    Rickels, Karl
    BIOLOGICAL PSYCHIATRY, 2011, 69 (09) : 90S - 91S
  • [33] INSOMNIA AND QUALITY OF LIFE IN GENERALIZED ANXIETY DISORDER: IMPACT ON CLINICAL PRESENTATION AND RESPONSE TO PREGABALIN AND VENLAFAXINE-XR
    Mychaskiw, M. A.
    Alvir, J. M.
    Herman, B. K.
    Pallanti, S.
    Joshi, A.
    EUROPEAN PSYCHIATRY, 2009, 24
  • [34] Generalized anxiety disorder - Longitudinal course and pharmacologic treatment
    Schweizer, E
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 1995, 18 (04) : 843 - &
  • [35] Venlafaxine in therapy of comorbid generalized anxiety disorder with depressive disorder
    Boerner, RJ
    NERVENHEILKUNDE, 2001, 20 (01) : 55 - 58
  • [36] Efficacy and safety of venlafaxine ER in the treatment of children and adolescents with generalized anxiety disorder
    Yeung, P
    Kunz, N
    Rynn, M
    Riddle, M
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S194 - S195
  • [37] Association analysis between the A118G polymorphism in the OPRM1 gene and treatment response to venlafaxine XR in generalized anxiety disorder
    Cooper, Alissa J.
    Rickels, Karl
    Lohoff, Falk W.
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2013, 28 (03) : 258 - 262
  • [38] Venlafaxine XR versus escitalopram treatment of major depressive disorder
    Zarra, J
    Schmidt, L
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S394 - S395
  • [39] A comparison of venlafaxine XR and paroxetine in the treatment of outpatients with panic disorder
    Pollack, M
    Whitaker, T
    Mangano, R
    Gao, B
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 : S201 - S202
  • [40] Escitalopram vs venlafaxine XR treatment of major depressive disorder
    Montgomery, SA
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S207 - S207